Gadobutrol - CAS 138071-82-6
Catalog number:
138071-82-6
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Description:
Gadobutrol is a gadolinium-based MRI contrast agent (GBCA). It received marketing approval in Canada and in the United States. As of 2007, it was the only GBCA approved at 1.0 molar concentrations. Gadobutrol is marketed by Bayer Schering Pharma as Gadovist, and by Bayer HealthCare Pharmaceuticals as Gadavist.
Publictions citing BOC Sciences Products
  • >> More
Purity:
0.98
Synonyms:
Gd-DO3A-butrol
MSDS:
Inquire
1.Free-breathing motion-corrected late-gadolinium-enhancement imaging improves image quality in children.
Olivieri L1,2, Cross R3, O'Brien KJ3,4, Xue H4, Kellman P4, Hansen MS4. Pediatr Radiol. 2016 Feb 17. [Epub ahead of print]
BACKGROUND: The value of late-gadolinium-enhancement (LGE) imaging in the diagnosis and management of pediatric and congenital heart disease is clear; however current acquisition techniques are susceptible to error and artifacts when performed in children because of children's higher heart rates, higher prevalence of sinus arrhythmia, and inability to breath-hold. Commonly used techniques in pediatric LGE imaging include breath-held segmented FLASH (segFLASH) and steady-state free precession-based (segSSFP) imaging. More recently, single-shot SSFP techniques with respiratory motion-corrected averaging have emerged.
2.Allergic-like Reactions to the MR Imaging Contrast Agent Gadobutrol: A Prospective Study of 32 991 Consecutive Injections.
Power S1, Talbot N1, Kucharczyk W1, Mandell DM1. Radiology. 2016 Apr 25:151066. [Epub ahead of print]
Purpose To determine the frequency and severity of allergic-like reactions to gadobutrol. Materials and Methods Data collection during the study period was part of a hospital quality assurance initiative to confirm the safety of gadobutrol after its introduction at this institute from 2010 to 2013. The study also included an electronic health records review approved by the institutional review board of the University Health Network, Toronto. The institutional review board waived the requirement for informed consent. At the time of each reaction to contrast material, the patient's age and sex, whether premedication was given, the contrast agent used, the volume injected, the patient's symptoms, and the treatment administered were recorded. Allergic-like reactions from physiologic reactions were differentiated and the frequency and severity of allergic-like reactions, the prevalence of risk factors for reactions, the frequency of reactions despite the use of premedication (a "breakthrough reaction"), and the frequency of delayed reactions were calculated.
3.Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function.
Murata N1, Gonzalez-Cuyar LF, Murata K, Fligner C, Dills R, Hippe D, Maravilla KR. Invest Radiol. 2016 Feb 8. [Epub ahead of print]
OBJECTIVE: The purpose of this study was to determine whether gadolinium (Gd) is deposited in brain and bone tissues in patients receiving only non-Group 1 agents, either macrocyclic or linear protein interacting Gd-based contrast agents, with normal renal function. Group 1 agents are linear agents most associated with nephrogenic systemic fibrosis that the US Federal Drug Administration has defined as contraindicated in patients at risk for this disease.
4.Safety of gadobutrol in over 23,000 patients: the GARDIAN study, a global multicentre, prospective, non-interventional study.
Prince MR1,2, Lee HG3, Lee CH4, Youn SW5, Lee IH6, Yoon W7, Yang B8, Wang H9, Wang J10, Shih TT11, Huang GS12, Lirng JF13, Palkowitsch P14; GARDIAN study group. Eur Radiol. 2016 Mar 9. [Epub ahead of print]
OBJECTIVES: To investigate the safety and tolerability of gadobutrol at the recommended dose in patients requiring contrast-enhanced magnetic resonance imaging/angiography (MRI/MRA) in the routine setting.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Chemical Structure

CAS 138071-82-6 Gadobutrol

Quick Inquiry

Verification code

Featured Items